- Home
- XFOR vs GNS Comparison
XFOR vs GNS Comparison
Compare XFOR & GNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- GNS
- Stock Information
- Founded
- XFOR 2014
- GNS 2002
- Country
- XFOR United States
- GNS Singapore
- Employees
- XFOR N/A
- GNS N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- GNS Other Consumer Services
- Sector
- XFOR Health Care
- GNS Real Estate
- Exchange
- XFOR Nasdaq
- GNS Nasdaq
- Market Cap
- XFOR 84.3M
- GNS 81.8M
- IPO Year
- XFOR N/A
- GNS 2022
- Fundamental
- Price
- XFOR $3.81
- GNS $0.82
- Analyst Decision
- XFOR Strong Buy
- GNS
- Analyst Count
- XFOR 3
- GNS 0
- Target Price
- XFOR $34.17
- GNS N/A
- AVG Volume (30 Days)
- XFOR 1.4M
- GNS 1.6M
- Earning Date
- XFOR 11-12-2025
- GNS 09-23-2025
- Dividend Yield
- XFOR N/A
- GNS N/A
- EPS Growth
- XFOR N/A
- GNS N/A
- EPS
- XFOR N/A
- GNS N/A
- Revenue
- XFOR $32,774,000.00
- GNS $5,749,894.00
- Revenue This Year
- XFOR $1,307.51
- GNS $62.23
- Revenue Next Year
- XFOR N/A
- GNS $69.63
- P/E Ratio
- XFOR N/A
- GNS N/A
- Revenue Growth
- XFOR 5721.31
- GNS N/A
- 52 Week Low
- XFOR $1.35
- GNS $0.21
- 52 Week High
- XFOR $26.83
- GNS $1.92
- Technical
- Relative Strength Index (RSI)
- XFOR 62.18
- GNS 43.16
- Support Level
- XFOR $2.96
- GNS $0.82
- Resistance Level
- XFOR $4.54
- GNS $0.90
- Average True Range (ATR)
- XFOR 0.27
- GNS 0.07
- MACD
- XFOR 0.07
- GNS -0.00
- Stochastic Oscillator
- XFOR 55.75
- GNS 20.55
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.